Sharekhan by BNP Paribas recommends buying the Zydus Lifesciences stock, setting a target price of Rs 1078. The pharmaceutical giant recently reported strong quarterly earnings, with profits up nearly 20% year-over-year. While revenue dipped slightly compared to the last quarter, Zydus' management projects double-digit growth in India and the US.
